Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Introduction: Blocking the colony-stimulating factor 1 (CSF-1) signal on tumor-associated macrophages can lead to an upregulation of checkpoint molecules, such as programmed cell death ligand 1 (PD-L1), thus causing resistance to this blockade. Combining spartalizumab (PDR001), a high-affinity, liga...

Full description

Bibliographic Details
Main Authors: Jibran Ahmed, Bettzy Stephen, Yali Yang, Evan Kwiatkowski, Chinenye Lynette Ejezie, Shubham Pant
Format: Article
Language:English
Published: Innovative Healthcare Institute 2024-05-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
lacnotuzumab
spartalizumab
pancreatic cancer
melanoma
endometrial cancer
Online Access:https://jipo.org/doi/pdf/10.36401/JIPO-23-16

Internet

https://jipo.org/doi/pdf/10.36401/JIPO-23-16

Similar Items